Corcept Therapeutics (CORT) Operating Margin (2012 - 2026)

Corcept Therapeutics has reported Operating Margin for 15 years, with the latest figure at 16.12% in Q2 2026.

• Quarterly Operating Margin rose 240.0% year-over-year to 16.12% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.77% (down 1347.0% YoY) and the FY2025 annual result came in at 5.88%, down 1440.0% from the prior year.
• Operating Margin improved to 16.12% in Q2 2026 per CORT's latest filing, from 30.08% in the prior quarter.
• Over five years, Operating Margin peaked at 31.39% in Q3 2022 and troughed at 30.08% in Q1 2026.
• A 5-year average of 16.13% and a median of 20.91% in 2024 frame the typical range for Operating Margin.
• The sharpest annual moves came in 2024 and 2026: Operating Margin surged 604 bps in 2024, then sank 3225 bps in 2026.
• Over 5 years, Operating Margin stood at 21.83% in 2022, then increased by 7 bps to 23.39% in 2023, then plunged by 41 bps to 13.89% in 2024, then sank by 84 bps to 2.22% in 2025, then soared by 626 bps to 16.12% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 16.12%, 30.08%, and 2.22% for Q2 2026, Q1 2026, and Q4 2025 respectively.